DexCom, Inc. $DXCM Shares Sold by Grimes & Company Inc.

Grimes & Company Inc. cut its holdings in DexCom, Inc. (NASDAQ:DXCM) by 0.7% in the 2nd quarter, HoldingsChannel reports. The fund owned 134,054 shares of the medical device company’s stock after selling 881 shares during the period. Grimes & Company Inc.’s holdings in DexCom were worth $11,702,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Golden State Wealth Management LLC increased its holdings in shares of DexCom by 211.2% during the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock worth $27,000 after buying an additional 264 shares during the last quarter. Zions Bancorporation National Association UT acquired a new stake in shares of DexCom during the 1st quarter worth $27,000. Anderson Financial Strategies LLC acquired a new stake in shares of DexCom during the 1st quarter worth $37,000. Alpine Bank Wealth Management acquired a new stake in shares of DexCom during the 1st quarter worth $40,000. Finally, Private Trust Co. NA increased its holdings in shares of DexCom by 99.4% during the 1st quarter. Private Trust Co. NA now owns 672 shares of the medical device company’s stock worth $46,000 after buying an additional 335 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

DXCM has been the subject of a number of research analyst reports. Morgan Stanley upped their price objective on DexCom from $82.00 to $89.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 15th. William Blair upgraded DexCom to a “strong-buy” rating in a report on Thursday, July 31st. Wall Street Zen downgraded DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, August 10th. Piper Sandler upped their price objective on DexCom from $90.00 to $100.00 and gave the stock an “overweight” rating in a report on Thursday, July 31st. Finally, The Goldman Sachs Group decreased their price target on shares of DexCom from $104.00 to $89.00 and set a “buy” rating for the company in a research report on Wednesday, October 1st. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and an average target price of $98.32.

Insider Activity at DexCom

In related news, Director Mark G. Foletta sold 2,750 shares of the stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $81.06, for a total transaction of $222,915.00. Following the sale, the director owned 51,121 shares in the company, valued at $4,143,868.26. This represents a 5.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Sadie Stern sold 1,466 shares of the stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $80.00, for a total transaction of $117,280.00. Following the sale, the executive vice president owned 105,223 shares in the company, valued at approximately $8,417,840. This trade represents a 1.37% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 6,849 shares of company stock worth $564,733. 0.32% of the stock is currently owned by company insiders.

DexCom Stock Performance

Shares of DXCM stock opened at $67.05 on Monday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. DexCom, Inc. has a one year low of $57.52 and a one year high of $93.25. The company’s 50-day simple moving average is $76.31 and its 200-day simple moving average is $77.93. The stock has a market capitalization of $26.29 billion, a price-to-earnings ratio of 46.56, a PEG ratio of 1.41 and a beta of 1.47.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, topping the consensus estimate of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. During the same quarter last year, the company posted $0.43 earnings per share. The company’s quarterly revenue was up 15.2% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. Equities analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.